Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.15 USD | +1.22% | +0.48% | -24.55% |
May. 15 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
Apr. 30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
Evolution of the average Target Price on Marker Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Marker Therapeutics, Inc.
Ladenburg Thalmann | |
Piper Sandler | |
Roth Capital Partners | |
Oppenheimer | |
Cantor Fitzgerald |
EPS Revisions
- Stock Market
- Equities
- MRKR Stock
- Consensus Marker Therapeutics, Inc.